PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1935182
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1935182
Injectable Drug Delivery Market is estimated to be valued at USD 650 Bn in 2026 and is expected to reach USD 900 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 650 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.00% | 2033 Value Projection: | USD 900 Bn |
Injectables offer maximum bioavailability of drugs towards the intended site of action and avoid the first pass metabolism. The injectable route is mostly preferred for the drugs which can't be taken orally or have some stability problems. Unconscious patients or patients having low compliance towards oral tablets or capsules can be preferred for the injectable drug delivery therapy.
Increasing prevalence of chronic diseases such as diabetes, cardiac diseases, and anaphylaxis has supported growth of global injectable drug delivery market. According to the Allergy, Asthma & Clinical Immunology, in 2015, around 15 million people suffered from food allergies in the U.K. Similarly, according to the European Academy of Allergy and Clinical Immunology (EAACI), in 2015, around 17 million people suffered from food allergies in the U.K., of which around 3.5 million were children. Increasing awareness regarding safety and concern of needlestick injuries is a major factor driving growth of the injectable drug delivery market. For instance, the WHO recommended the use of safety syringes with sharp injury protection (SIP), in order to prevent needlestick injuries. Similarly, in May 2017, Innovative Neurons LLC announced to commercialize its patented auto retractable multi-needle syringe known as FAST (fast, accessible, safe, and technology) to decrease needlestick injuries. Various market players are focusing on the development and advancement in this space. For instance, ACT-O-VIAL System offered by Pfizer Inc. is a dual-component vial system that allows reconstitution of sterile, injectable medications by pressing on the plastic cap. The facility launch by market players to cater requirements of patients is expected to drive the market growth. For instance, in July 2018, Pfizer, Inc. announced to build sterile injectable pharmaceutical production facilities in the Michigan, U.S.
However, product recalls by the manufacturers is the major factors restraining the market over the forecast period. For instance, in April 2018, Becton Dickson and Company announced a recall of PosiFlush Heaparin Lock Flush Syringe, and Prefilled normal saline syringe, owing to the contamination with Serratia marcescens bacterium.
Key features of the study